Markets

Celldex Therapeutics (CLDX) Soars: Stock Adds 12.6% in Session - Tale of the Tape

Celldex Therapeutics, Inc. ( CLDX ) was a big mover last session, as its shares rose nearly 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the trend for the healthcare company since May 15, as the stock is now trading above the volatile price range of $12.59 to $14.89.

In the last 30 days, the company witnessed one negative estimate revision and the Zacks Consensus Estimate also moved lower, suggesting trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday's move higher lasts.

Celldex Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Other better-ranked stocks in the medical sector include Gilead Sciences Inc. ( GILD ), ANI Pharmaceuticals, Inc. ( ANIP ) and Illumina Inc. ( ILMN ). All three sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CELLDEX THERAPT (CLDX): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD ANIP CLDX ILMN

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More